Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trial

美罗华 医学 青少年皮肌炎 多发性肌炎 随机对照试验 内科学 安慰剂 耐火材料(行星科学) 临床终点 皮肌炎 肌肉无力 物理疗法 外科 病理 替代医学 物理 淋巴瘤 天体生物学
作者
Chester V. Oddis,Ann M. Reed,Rohit Aggarwal,Lisa G. Rider,Dana P. Ascherman,Marc C. Levesque,Richard J. Barohn,Brian M. Feldman,Michael O. Harris‐Love,Diane Koontz,Noreen Fertig,Stephanie Kelley,Sherrie L. Pryber,Frederick W. Miller,Howard E. Rockette
出处
期刊:Arthritis & Rheumatism [Wiley]
卷期号:65 (2): 314-324 被引量:580
标识
DOI:10.1002/art.37754
摘要

Abstract Objective To assess the safety and efficacy of rituximab in a randomized, double‐blind, placebo‐phase trial in adult and pediatric myositis patients. Methods Adults with refractory polymyositis (PM) and adults and children with refractory dermatomyositis (DM) were enrolled. Entry criteria included muscle weakness and ≥2 additional abnormal values on core set measures (CSMs) for adults. Juvenile DM patients required ≥3 abnormal CSMs, with or without muscle weakness. Patients were randomized to receive either rituximab early or rituximab late, and glucocorticoid or immunosuppressive therapy was allowed at study entry. The primary end point compared the time to achieve the International Myositis Assessment and Clinical Studies Group preliminary definition of improvement (DOI) between the 2 groups. The secondary end points were the time to achieve ≥20% improvement in muscle strength and the proportions of patients in the early and late rituximab groups achieving the DOI at week 8. Results Among 200 randomized patients (76 with PM, 76 with DM, and 48 with juvenile DM), 195 showed no difference in the time to achieving the DOI between the rituximab late (n = 102) and rituximab early (n = 93) groups ( P = 0.74 by log rank test), with a median time to achieving a DOI of 20.2 weeks and 20.0 weeks, respectively. The secondary end points also did not significantly differ between the 2 treatment groups. However, 161 (83%) of the randomized patients met the DOI, and individual CSMs improved in both groups throughout the 44‐week trial. Conclusion Although there were no significant differences in the 2 treatment arms for the primary and secondary end points, 83% of adult and juvenile myositis patients with refractory disease met the DOI. The role of B cell–depleting therapies in myositis warrants further study, with consideration for a different trial design.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SYLH应助顺心的惜蕊采纳,获得10
1秒前
天天快乐应助顺心的惜蕊采纳,获得10
1秒前
小马甲应助是臻不是真采纳,获得10
1秒前
1秒前
shilong.yang发布了新的文献求助10
1秒前
呆萌代桃发布了新的文献求助10
1秒前
1秒前
淡淡书文完成签到,获得积分10
2秒前
葛稀发布了新的文献求助10
2秒前
2秒前
ljs完成签到,获得积分10
3秒前
4秒前
4秒前
云之南完成签到,获得积分20
5秒前
情怀应助biubiudididi采纳,获得10
5秒前
YU发布了新的文献求助10
5秒前
Lucas应助Run采纳,获得10
5秒前
Qiao应助djbj2022采纳,获得80
5秒前
6秒前
莉莉子完成签到,获得积分10
6秒前
特西之魂完成签到 ,获得积分10
6秒前
万能图书馆应助aaa采纳,获得10
6秒前
糟糕的学姐完成签到,获得积分10
6秒前
小华发布了新的文献求助10
6秒前
清新的夜柳完成签到,获得积分10
7秒前
7秒前
7秒前
活力的秋莲完成签到,获得积分10
7秒前
ljxx发布了新的文献求助10
8秒前
SYLH应助刘强采纳,获得10
9秒前
pluto应助奋斗小公主采纳,获得10
9秒前
LLLLXR发布了新的文献求助10
9秒前
9秒前
小乐应助zhengmin采纳,获得30
10秒前
10秒前
11秒前
楚江南完成签到,获得积分10
11秒前
我爱亲柠檬完成签到,获得积分10
11秒前
12秒前
loomcool完成签到,获得积分10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969383
求助须知:如何正确求助?哪些是违规求助? 3514211
关于积分的说明 11172730
捐赠科研通 3249476
什么是DOI,文献DOI怎么找? 1794909
邀请新用户注册赠送积分活动 875441
科研通“疑难数据库(出版商)”最低求助积分说明 804827